[278] CHRONISENSE

Danny Lange[1], [1] Chronisense Medical, Ltd.

- **Investment Rational**
  No other wrist-wearable, clinically approved and Internet-connected, chronic patient medical monitor is on the market.
  ChroniSense's management is focusing on forging strategic partnerships with the relevant market leaders in the digital and remote health arenas.

- **Business Strategy**
  The main hardware element is a watch-type wearable monitor, with infrastructure for Internet-based telemedicine. Separate apps support chronic disease patients and physicians, and parents/guardians/institutions. Near-term revenues will be based on sales/distribution through physicians, hospitals, and other institutions; long-term through pharmacies and other retails channels as allowed by prescription.

- **Core Technology**
  ChroniSense's main product platform is a clinical-quality, wrist-wearable medical sensor. Our prototype includes pulse oximeter/PPG, ECG, pulse sensor, and positional monitor; algorithms allow estimation of blood pressure and PPG parameters. The system communicates with smartphone/PC; advanced analysis and long-term data storage are performed on PC/smartphone, with Internet communications/storage capability.
  Such continuous mobile medical monitoring has potential to benefit chronic disease sufferers, not only by detecting acute distress episodes, but by tracking health status changes. No other product will do such multi-parameter long-term medical follow-up of chronically ill patients while allowing an active, normal life.

- **Product Profile/Pipeline**
  Our device prototypes have successfully undergone calibration trials at an FDA-recognized laboratory. Hospital trials in planning shall include those with CHF and COPD, representing a multi-billion dollar market in USA. Product launch is scheduled for early 2018. We anticipate marketing to medical institutions and insurance companies, based on improving quality of patient life by allowing safe home discharge. We will pursue collaboration and partnerships with medical device manufacturers, who may license our technologies, or support integration into their existing telemedicine systems.

What's Next?

We are currently engaged in various stages of testing initial elements of the first generation device. Simultaneously, we are developing second generation parameter sensors and test algorithms.